Company: NCNA
Filing Date: 2025-04-29
Form Type: F-1/A
Source: 0001193125-25-103135
Chunk: 22

Company: NuCana plc
Filing Date: 2025-04-29
Form: F-1/A
Chunk 22
---
-Funded Warrants, Series A Warrants and Series B Warrants will have no rights with respect to the ADSs
underlying such Pre-Funded Warrants and Warrants. Upon exercise of the Pre-Funded Warrants, Series A Warrants and Series B Warrants, as applicable, the holders will be
entitled to exercise the rights of an ADS holder only as to matters for which the record date occurs after the exercise date.

The Pre-FundedWarrants, Series A Warrants and Series B Warrants are speculative in nature.

The Pre-Funded Warrants, Series A Warrants and Series B Warrants do not confer any rights of ADS ownership on their respective holders, such as voting rights or the right to receive dividends, but rather merely
represent the right to acquire ADSs at a fixed price.

9

Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.

In addition to
rights and remedies available to all purchasers in this offering under federal securities law and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The
ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including, but not limited to: (i) timely delivery of
securities; (ii) agreement to not enter into variable rate financings for three months from closing, subject to exceptions; (iii) agreement to not enter into any financings for 90 days from closing; and (iv) indemnification for breach
of contract.

The Series A Warrants and Series B Warrants may not have value.

The Series A Warrants being offered by us in this offering have an exercise price equal to 125% of the combined public offering price, and
expire on the five-year anniversary of the Initial Exercise Date. The Series B Warrants being offered by us in this offering have an exercise price equal to 250% of the combined public offering price, and expire on the two and one-half (2.5)-year anniversary of the Initial Exercise Date. In the event that the prevailing market price of our ADSs does not exceed the exercise price of the Series A Warrants or Series B Warrants, as
applicable, during the period when such Warrants are exercisable, such Warrants may not have any value. There can